Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation

The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lina, Schwartzman, Jacob, Gibbs, Angela, Lisac, Robert, Kleinschmidt, Richard, Wilmot, Beth, Bottomly, Daniel, Coleman, Ilsa, Nelson, Peter, McWeeney, Shannon, Alumkal, Joshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660401/
https://www.ncbi.nlm.nih.gov/pubmed/23704919
http://dx.doi.org/10.1371/journal.pone.0063563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660401/
https://www.ncbi.nlm.nih.gov/pubmed/23704919
http://dx.doi.org/10.1371/journal.pone.0063563

Ejemplares similares